이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

저등급 신경아교종 환자의 약물 셀루메티닙 대 카보플라틴 및 빈크리스틴에 대한 연구

2026년 11월 5일 업데이트: National Cancer Institute (NCI)

BRAFV600E 돌연변이 또는 전신성 신경섬유종증 1형(NF1)과 연관되지 않은 신규 진단 또는 이전에 치료받지 않은 저등급 신경아교종(LGG)에서 카보플라틴 및 빈크리스틴 대 셀루메티닙(NSC# 748727)의 3상 무작위 비열등성 연구

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVE:

I. To demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior compared to treatment with carboplatin/vincristine (CV) in previously-untreated low-grade glioma (LGG) not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1).

SECONDARY OBJECTIVES:

I. To estimate tumor response rates to each regimen of chemotherapy. II. To evaluate visual acuity (VA) outcomes utilizing Teller Acuity Cards (TAC) and HOTV letter acuity testing in previously-untreated optic pathway gliomas (OPGs).

III. To describe the improvement in motor function as measured by the Vineland Scale in children with previously-untreated LGG that have motor deficits at enrollment.

IV. To estimate the difference in EFS and tumor response rate between BRAF rearranged and non-BRAF rearranged patients treated on each chemotherapy regimen.

V. To prospectively evaluate the quality of life of children with LGG not associated with BRAFV600E or systemic NF1 treated with either CV or selumetinib.

VI. To prospectively evaluate the cognitive, social, emotional, and behavioral functioning of children with LGG not associated with BRAFV600E or systemic NF1 treated with either CV or selumetinib.

EXPLORATORY OBJECTIVE:

I. To obtain paired blood and tumor specimens for future biology studies as well as data from Molecular Characterization Initiative (MCI) testing, to correlate genomic drivers to efficacy outcomes.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I:

INDUCTION: Patients receive vincristine sulfate intravenously (IV) on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and magnetic resonance imaging (MRI) throughout the trial.

MAINTENANCE: Patients receive vincristine sulfate IV on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and MRI throughout the trial.

ARM II: Patients receive selumetinib sulfate orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) at baseline and undergo collection of blood and MRI throughout the trial.

After completion of study treatment, patients are followed up every 3 months for year 1, every 6 months for years 2-3, and then annually for years 4-10.

연구 유형

중재적

등록 (추정된)

170

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 모병
        • Children's Hospital of Alabama
        • 연락하다:
        • 수석 연구원:
          • Laura K. Metrock
    • Arizona
      • Mesa, Arizona, 미국, 85202
        • 모병
        • Banner Children's at Desert
        • 연락하다:
          • Site Public Contact
          • 전화번호: 480-412-3100
        • 수석 연구원:
          • Joseph C. Torkildson
      • Phoenix, Arizona, 미국, 85016
        • 모병
        • Phoenix Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 602-546-0920
        • 수석 연구원:
          • Kazuhiro Sabet
    • Arkansas
      • Little Rock, Arkansas, 미국, 72202-3591
        • 모병
        • Arkansas Children's Hospital
        • 수석 연구원:
          • Michael W. Bishop
        • 연락하다:
          • Site Public Contact
          • 전화번호: 501-364-7373
    • California
      • Loma Linda, California, 미국, 92354
        • 모병
        • Loma Linda University Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 909-558-4050
        • 수석 연구원:
          • Albert Kheradpour
      • Long Beach, California, 미국, 90806
        • 모병
        • Miller Children's and Women's Hospital Long Beach
        • 연락하다:
          • Site Public Contact
          • 전화번호: 562-933-5600
        • 수석 연구원:
          • Jacqueline N. Casillas
      • Los Angeles, California, 미국, 90027
        • 모병
        • Children's Hospital Los Angeles
        • 연락하다:
          • Site Public Contact
          • 전화번호: 323-361-4110
        • 수석 연구원:
          • Nathan J. Robison
      • Los Angeles, California, 미국, 90048
        • 모병
        • Cedars-Sinai Medical Center
        • 수석 연구원:
          • Fataneh (Fae) Majlessipour
        • 연락하다:
      • Los Angeles, California, 미국, 90095
        • 모병
        • Mattel Children's Hospital UCLA
        • 연락하다:
          • Site Public Contact
          • 전화번호: 310-825-6708
        • 수석 연구원:
          • Satiro N. De Oliveira
      • Oakland, California, 미국, 94611
        • 모병
        • Kaiser Permanente-Oakland
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-642-4691
          • 이메일: Kpoct@kp.org
        • 수석 연구원:
          • Aarati V. Rao
      • Orange, California, 미국, 92868
        • 모병
        • Children's Hospital of Orange County
        • 연락하다:
        • 수석 연구원:
          • Elyssa M. Rubin
      • Palo Alto, California, 미국, 94304
        • 모병
        • Lucile Packard Children's Hospital Stanford University
        • 연락하다:
        • 수석 연구원:
          • Jay Michael S. Balagtas
      • San Diego, California, 미국, 92123
        • 모병
        • Rady Children's Hospital - San Diego
        • 연락하다:
          • Site Public Contact
          • 전화번호: 858-966-5934
        • 수석 연구원:
          • William D. Roberts
      • San Francisco, California, 미국, 94158
        • 모병
        • UCSF Medical Center-Mission Bay
        • 연락하다:
        • 수석 연구원:
          • Alyssa T. Reddy
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • Children's Hospital Colorado
        • 수석 연구원:
          • Jean M. Mulcahy Levy
        • 연락하다:
    • Connecticut
      • Hartford, Connecticut, 미국, 06106
        • 모병
        • Connecticut Children's Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 860-545-9981
        • 수석 연구원:
          • Michael S. Isakoff
      • New Haven, Connecticut, 미국, 06520
        • 모병
        • Yale University
        • 수석 연구원:
          • Asher M. Marks
        • 연락하다:
    • Delaware
      • Wilmington, Delaware, 미국, 19803
        • 모병
        • Alfred I duPont Hospital for Children
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • 모병
        • Children's National Medical Center
        • 수석 연구원:
          • Jeffrey S. Dome
        • 연락하다:
    • Florida
      • Fort Myers, Florida, 미국, 33908
        • 모병
        • Golisano Children's Hospital of Southwest Florida
        • 연락하다:
        • 수석 연구원:
          • Emad K. Salman
      • Gainesville, Florida, 미국, 32610
        • 모집하지 않고 적극적으로
        • UF Health Cancer Institute - Gainesville
      • Hollywood, Florida, 미국, 33021
        • 모병
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 954-265-1847
          • 이메일: OHR@mhs.net
        • 수석 연구원:
          • Iftikhar Hanif
      • Jacksonville, Florida, 미국, 32207
        • 모병
        • Nemours Children's Clinic-Jacksonville
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
      • Miami, Florida, 미국, 33155
        • 모병
        • Nicklaus Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 888-624-2778
        • 수석 연구원:
          • Ziad A. Khatib
      • Miami, Florida, 미국, 33136
        • 빼는
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Orlando, Florida, 미국, 32806
        • 모병
        • Arnold Palmer Hospital for Children
        • 연락하다:
        • 수석 연구원:
          • Zhongbo Hu
      • Orlando, Florida, 미국, 32827
        • 모병
        • Nemours Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
      • Orlando, Florida, 미국, 32803
        • 모병
        • AdventHealth Orlando
        • 연락하다:
        • 수석 연구원:
          • Fouad M. Hajjar
      • Pensacola, Florida, 미국, 32504
        • 정지된
        • Sacred Heart Hospital
      • Pensacola, Florida, 미국, 32504
      • St. Petersburg, Florida, 미국, 33701
        • 모병
        • Johns Hopkins All Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Stacie L. Stapleton
      • Tampa, Florida, 미국, 33607
        • 모병
        • Saint Joseph's Hospital/Children's Hospital-Tampa
        • 연락하다:
        • 수석 연구원:
          • Don E. Eslin
    • Georgia
      • Atlanta, Georgia, 미국, 30329
        • 모병
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • 수석 연구원:
          • Jason R. Fangusaro
        • 연락하다:
    • Hawaii
      • Honolulu, Hawaii, 미국, 96826
        • 모병
        • Kapiolani Medical Center for Women and Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 808-983-6090
        • 수석 연구원:
          • Wade T. Kyono
    • Idaho
      • Boise, Idaho, 미국, 83712
        • 모병
        • Saint Luke's Cancer Institute - Boise
        • 수석 연구원:
          • Martha M. Pacheco
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Lurie Children's Hospital-Chicago
        • 연락하다:
          • Site Public Contact
          • 전화번호: 773-880-4562
        • 수석 연구원:
          • Angela J. Waanders
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Wendy S. Darlington
      • Chicago, Illinois, 미국, 60612
        • 모병
        • University of Illinois
        • 연락하다:
          • Site Public Contact
          • 전화번호: 312-355-3046
        • 수석 연구원:
          • Dipti S. Dighe
      • Peoria, Illinois, 미국, 61637
      • Springfield, Illinois, 미국, 62702
        • 모병
        • Southern Illinois University School of Medicine
        • 연락하다:
          • Site Public Contact
          • 전화번호: 217-545-7929
        • 수석 연구원:
          • Gregory P. Brandt
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • 모병
        • Riley Hospital for Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-248-1199
        • 수석 연구원:
          • Sandeep Batra
      • Indianapolis, Indiana, 미국, 46260
        • 모병
        • Ascension Saint Vincent Indianapolis Hospital
        • 연락하다:
        • 수석 연구원:
          • Jessica F. Goodman
    • Iowa
      • Des Moines, Iowa, 미국, 50309
        • 모병
        • Blank Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Samantha L. Mallory
      • Iowa City, Iowa, 미국, 52242
        • 모병
        • University of Iowa/Holden Comprehensive Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-237-1225
        • 수석 연구원:
          • Andrew P. Groves
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • 모병
        • University of Kentucky/Markey Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 859-257-3379
        • 수석 연구원:
          • James T. Badgett
      • Louisville, Kentucky, 미국, 40202
        • 모병
        • Norton Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Michael J. Ferguson
    • Louisiana
      • New Orleans, Louisiana, 미국, 70118
        • 모병
        • Children's Hospital New Orleans
        • 수석 연구원:
          • Maria C. Velez-Yanguas
        • 연락하다:
          • Site Public Contact
          • 전화번호: 504-894-5377
    • Maine
      • Bangor, Maine, 미국, 04401
        • 모병
        • Eastern Maine Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 207-973-4274
        • 수석 연구원:
          • Daniel L. Callaway
      • Scarborough, Maine, 미국, 04074
        • 모병
        • Maine Children's Cancer Program
        • 수석 연구원:
          • Stanley Chaleff
        • 연락하다:
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Kenneth J. Cohen
      • Bethesda, Maryland, 미국, 20889-5600
        • 모병
        • Walter Reed National Military Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 301-319-2100
        • 수석 연구원:
          • Kip R. Hartman
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 모집하지 않고 적극적으로
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, 미국, 02114
        • 모집하지 않고 적극적으로
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • C S Mott Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-865-1125
        • 수석 연구원:
          • Andrea T. Franson
      • Detroit, Michigan, 미국, 48201
      • Grand Rapids, Michigan, 미국, 49503
        • 모병
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, 미국, 48073
        • 모집하지 않고 적극적으로
        • Corewell Health Children's
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55404
        • 모병
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • 수석 연구원:
          • Michael K. Richards
        • 연락하다:
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota/Masonic Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 612-624-2620
        • 수석 연구원:
          • Clay M. Hoerig
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic in Rochester
        • 연락하다:
          • Site Public Contact
          • 전화번호: 855-776-0015
        • 수석 연구원:
          • Joseph Z. Wilson
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • 모병
        • University of Mississippi Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 601-815-6700
        • 수석 연구원:
          • Amanda Strobel
    • Missouri
      • Kansas City, Missouri, 미국, 64108
        • 모병
        • Children's Mercy Hospitals and Clinics
        • 수석 연구원:
          • Keith J. August
        • 연락하다:
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine
        • 연락하다:
        • 수석 연구원:
          • Andrew S. Cluster
      • St Louis, Missouri, 미국, 63104
        • 모병
        • Cardinal Glennon Children's Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 314-268-4000
        • 수석 연구원:
          • William S. Ferguson
    • Nebraska
      • Omaha, Nebraska, 미국, 68114
        • 모병
        • Children's Hospital and Medical Center of Omaha
        • 연락하다:
          • Site Public Contact
          • 전화번호: 402-955-3949
        • 수석 연구원:
          • Jill C. Beck
      • Omaha, Nebraska, 미국, 68198
        • 모병
        • University of Nebraska Medical Center
        • 연락하다:
        • 수석 연구원:
          • Jill C. Beck
    • New Jersey
      • Morristown, New Jersey, 미국, 07960
        • 모병
        • Morristown Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 973-971-5900
        • 수석 연구원:
          • Kathryn L. Laurie
    • New York
      • Albany, New York, 미국, 12208
        • 모병
        • Albany Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 518-262-5513
        • 수석 연구원:
          • Lauren R. Weintraub
      • Buffalo, New York, 미국, 14263
        • 모병
        • Roswell Park Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Matthew J. Barth
      • Mineola, New York, 미국, 11501
        • 모병
        • NYU Langone Hospital - Long Island
        • 연락하다:
        • 수석 연구원:
          • Chana L. Glasser
      • New Hyde Park, New York, 미국, 11040
        • 모병
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • 연락하다:
          • Site Public Contact
          • 전화번호: 718-470-3460
        • 수석 연구원:
          • Mark P. Atlas
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-639-7592
        • 수석 연구원:
          • Sameer Farouk Sait
      • New York, New York, 미국, 10016
        • 모병
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • 수석 연구원:
          • Elizabeth A. Raetz
        • 연락하다:
      • Rochester, New York, 미국, 14642
        • 모집하지 않고 적극적으로
        • University of Rochester
      • Syracuse, New York, 미국, 13210
        • 모병
        • State University of New York Upstate Medical University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 315-464-5476
        • 수석 연구원:
          • Melanie A. Comito
      • Valhalla, New York, 미국, 10595
        • 모병
        • New York Medical College
        • 연락하다:
          • Site Public Contact
          • 전화번호: 914-594-3794
        • 수석 연구원:
          • Andrew J. Bellantoni
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • 모병
        • UNC Lineberger Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • David E. Kram
      • Charlotte, North Carolina, 미국, 28203
        • 모병
        • Carolinas Medical Center/Levine Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-804-9376
        • 수석 연구원:
          • Joel A. Kaplan
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke University Medical Center
        • 수석 연구원:
          • Jessica M. Sun
        • 연락하다:
          • Site Public Contact
          • 전화번호: 888-275-3853
      • Greenville, North Carolina, 미국, 27834
        • 모병
        • East Carolina University
        • 연락하다:
        • 수석 연구원:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, 미국, 27157
        • 모병
        • Wake Forest University Health Sciences
        • 연락하다:
          • Site Public Contact
          • 전화번호: 336-713-6771
        • 수석 연구원:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, 미국, 58122
    • Ohio
      • Akron, Ohio, 미국, 44308
        • 모병
        • Children's Hospital Medical Center of Akron
        • 연락하다:
          • Site Public Contact
          • 전화번호: 330-543-3193
        • 수석 연구원:
          • Lauren R. Draper
      • Cincinnati, Ohio, 미국, 45229
        • 모병
        • Cincinnati Children's Hospital Medical Center
        • 연락하다:
        • 수석 연구원:
          • Peter M. de Blank
      • Cleveland, Ohio, 미국, 44106
        • 모병
        • Rainbow Babies and Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 216-844-5437
        • 수석 연구원:
          • Duncan S. Stearns
      • Columbus, Ohio, 미국, 43205
      • Dayton, Ohio, 미국, 45404
        • 모병
        • Dayton Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-228-4055
        • 수석 연구원:
          • Jordan M. Wright
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma Health Sciences Center
        • 연락하다:
        • 수석 연구원:
          • Rene Y. McNall-Knapp
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health and Science University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 503-494-1080
          • 이메일: trials@ohsu.edu
        • 수석 연구원:
          • Neha J. Patel
    • Pennsylvania
      • Danville, Pennsylvania, 미국, 17822
        • 모병
        • Geisinger Medical Center
        • 수석 연구원:
          • Jagadeesh Ramdas
        • 연락하다:
      • Hershey, Pennsylvania, 미국, 17033
        • 모병
        • Penn State Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 717-531-6012
        • 수석 연구원:
          • Lisa M. McGregor
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Children's Hospital of Philadelphia
        • 수석 연구원:
          • Michael J. Fisher
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19134
        • 모병
        • Saint Christopher's Hospital for Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 215-427-8991
        • 수석 연구원:
          • Gregory E. Halligan
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • Children's Hospital of Pittsburgh of UPMC
        • 연락하다:
        • 수석 연구원:
          • James T. Felker
    • Rhode Island
      • Providence, Rhode Island, 미국, 02903
        • 모병
        • Rhode Island Hospital
        • 수석 연구원:
          • Bradley DeNardo
        • 연락하다:
          • Site Public Contact
          • 전화번호: 401-444-1488
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina
        • 연락하다:
        • 수석 연구원:
          • Jacqueline M. Kraveka
      • Columbia, South Carolina, 미국, 29203
        • 모병
        • Prisma Health Richland Hospital
        • 수석 연구원:
          • Stuart L. Cramer
        • 연락하다:
      • Greenville, South Carolina, 미국, 29605
        • 모병
        • BI-LO Charities Children's Cancer Center
        • 수석 연구원:
          • Aniket Saha
        • 연락하다:
    • Tennessee
      • Knoxville, Tennessee, 미국, 37916
        • 모병
        • East Tennessee Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 865-541-8266
        • 수석 연구원:
          • Susan E. Spiller
      • Memphis, Tennessee, 미국, 38105
        • 모병
        • Saint Jude Children's Research Hospital
        • 수석 연구원:
          • Anna Vinitsky
        • 연락하다:
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University/Ingram Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-811-8480
        • 수석 연구원:
          • Devang J. Pastakia
    • Texas
      • Austin, Texas, 미국, 78723
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwestern/Simmons Cancer Center-Dallas
        • 연락하다:
        • 수석 연구원:
          • Daniel C. Bowers
      • El Paso, Texas, 미국, 79905
        • 모병
        • El Paso Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Benjamin Carcamo
      • Fort Worth, Texas, 미국, 76104
      • Houston, Texas, 미국, 77030
        • 모병
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • 수석 연구원:
          • Murali M. Chintagumpala
        • 연락하다:
          • Site Public Contact
          • 전화번호: 713-798-1354
          • 이메일: burton@bcm.edu
      • Houston, Texas, 미국, 77030
        • 모병
        • UT MD Anderson Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Najat C. Daw
      • Lubbock, Texas, 미국, 79410
        • 모병
        • Covenant Children's Hospital
        • 수석 연구원:
          • Kishor M. Bhende
        • 연락하다:
      • Lubbock, Texas, 미국, 79415
        • 모병
        • UMC Cancer Center / UMC Health System
        • 연락하다:
          • Site Public Contact
          • 전화번호: 806-775-8590
        • 수석 연구원:
          • Erin K. Barr
      • San Antonio, Texas, 미국, 78207
        • 모병
        • Children's Hospital of San Antonio
        • 연락하다:
        • 수석 연구원:
          • Julie Voeller
      • San Antonio, Texas, 미국, 78229
        • 모병
        • University of Texas Health Science Center at San Antonio
        • 연락하다:
        • 수석 연구원:
          • Shafqat Shah
      • San Antonio, Texas, 미국, 78229
        • 모병
        • Methodist Children's Hospital of South Texas
        • 연락하다:
        • 수석 연구원:
          • Jose M. Esquilin
    • Utah
      • Salt Lake City, Utah, 미국, 84113
        • 모병
        • Primary Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 801-585-5270
        • 수석 연구원:
          • Priya Chan
    • Vermont
      • Burlington, Vermont, 미국, 05405
        • 모병
        • University of Vermont and State Agricultural College
        • 연락하다:
          • Site Public Contact
          • 전화번호: 802-656-8990
          • 이메일: rpo@uvm.edu
        • 수석 연구원:
          • Jessica L. Heath
    • Virginia
      • Norfolk, Virginia, 미국, 23507
        • 모병
        • Children's Hospital of The King's Daughters
        • 연락하다:
        • 수석 연구원:
          • Melissa S. Mark
      • Richmond, Virginia, 미국, 23298
        • 모병
        • VCU Massey Comprehensive Cancer Center
        • 수석 연구원:
          • Christopher Park
        • 연락하다:
      • Roanoke, Virginia, 미국, 24014
        • 모병
        • Carilion Children's
        • 연락하다:
        • 수석 연구원:
          • Erwood G. Edwards
    • Washington
      • Seattle, Washington, 미국, 98105
        • 모병
        • Seattle Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 866-987-2000
        • 수석 연구원:
          • Sarah E. Leary
      • Spokane, Washington, 미국, 99204
        • 모병
        • Providence Sacred Heart Medical Center and Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Judy L. Felgenhauer
      • Tacoma, Washington, 미국, 98405
        • 모병
        • Mary Bridge Children's Hospital and Health Center
        • 연락하다:
        • 수석 연구원:
          • Robert G. Irwin
      • Tacoma, Washington, 미국, 98431
        • 모병
        • Madigan Army Medical Center
        • 수석 연구원:
          • Melissa A. Forouhar
        • 연락하다:
    • West Virginia
      • Morgantown, West Virginia, 미국, 26506
        • 모병
        • West Virginia University Healthcare
        • 연락하다:
        • 수석 연구원:
          • Ashley E. Meyer
    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • 모병
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • 연락하다:
        • 수석 연구원:
          • Nicholas J. Pytel
      • Milwaukee, Wisconsin, 미국, 53226
        • 모병
        • Children's Hospital of Wisconsin
        • 연락하다:
          • Site Public Contact
          • 전화번호: 414-955-4727
          • 이메일: MACCCTO@mcw.edu
        • 수석 연구원:
          • Sarah Rumler
  • 캐나다
      • Québec, 캐나다, G1V 4G2
        • 모병
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • 수석 연구원:
          • Bruno Michon
        • 연락하다:
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6H 3V4
        • 모병
        • British Columbia Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 6477 604-875-2345
        • 수석 연구원:
          • Rebecca J. Deyell
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
        • 모병
        • Janeway Child Health Centre
        • 수석 연구원:
          • Lisa A. Goodyear
        • 연락하다:
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3K 6R8
        • 모병
        • IWK Health Centre
        • 연락하다:
        • 수석 연구원:
          • Chelsea Ash
    • Quebec
      • Montreal, Quebec, 캐나다, H3H 1P3
        • 모병
        • The Montreal Children's Hospital of the MUHC
        • 연락하다:
        • 수석 연구원:
          • Stephanie Mourad
      • Montreal, Quebec, 캐나다, H3T 1C5
        • 모병
        • Centre Hospitalier Universitaire Sainte-Justine
        • 수석 연구원:
          • Monia Marzouki
        • 연락하다:
      • Sherbrooke, Quebec, 캐나다, J1H 5N4
        • 모병
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • 연락하다:
        • 수석 연구원:
          • Stephanie Vairy
  • 푸에르토 리코
      • Caguas, 푸에르토 리코, 00726
        • 모집하지 않고 적극적으로
        • HIMA San Pablo Oncologic Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must be >= 2 years and =< 21 years at the time of enrollment

  • Patients must have a body surface area (BSA) of >= 0.5 m^2 at enrollment

  • Patients must have non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1 (NCT02402244) Childhood Cancer Data Initiative (CCDI)-MCI, or accepted Clinical Laboratory Improvement Act (CLIA)-certified test and that has not been treated with any modality besides surgery. Note: Patients may be newly-diagnosed OR previously diagnosed, and there is no required time frame between biopsy/surgery and treatment initiation.

    • Patients with residual tumor after resection or progressive tumor after initial diagnosis (with or without surgery) who have not received treatment (chemotherapy and/or radiation) are eligible
    • Patients must have two-dimensional measurable tumor >= 1 cm^2 to be eligible
    • Patients with ependymoma are not eligible

  • Eligible histologies will include all tumors considered low-grade glioma or low-grade astrocytoma (World Health Organization [WHO] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma

  • Patients with metastatic disease or multiple independent primary LGG are eligible

  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (performed within 7 days prior to enrollment):

    • Age: Maximum Serum Creatinine (mg/dL)
    • 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
    • 6 to < 10 years: 1 mg/dL (male); 1 mg/dL (female)
    • 10 to < 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female)
    • 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
    • >= 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)

  • Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment) (children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect [unconjugated] bilirubin levels as long as their direct [conjugated] bilirubin is < 3.1 mg/dL)

  • Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (performed within 7 days prior to enrollment). For the purpose of this study, the ULN for SGPT is 45 U/L

  • Albumin >= 2 g/dL (performed within 7 days prior to enrollment)

  • Left ventricular ejection fraction (LVEF) >= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram (performed within 4 weeks prior to enrollment)

  • Corrected QT (QTc) interval =< 450 msec by electrocardiography (EKG) (performed within 4 weeks prior to enrollment)

  • Absolute neutrophil count >= 1,000/uL (unsupported) (performed within 7 days prior to enrollment)

  • Platelets >= 100,000/uL (unsupported) (performed within 7 days prior to enrollment)

  • Hemoglobin >= 8 g/dL (may be supported) (performed within 7 days prior to enrollment)

  • Patients with a known seizure disorder must be stable and must not have experienced a significant increase in seizure frequency within 2 weeks prior to enrollment

  • Patients 2-17 years of age must have a blood pressure that is =< 95th percentile for age, height, and sex at the time of enrollment (with or without the use of anti-hypertensive medications)

  • Patients >= 18 years of age must have a blood pressure =< 130/80 mmHg at the time of enrollment (with or without the use of anti-hypertensive medications)

  • Note for patients of all ages: Adequate blood pressure can be achieved using medication for the treatment of hypertension

  • All patients must have ophthalmology toxicity assessments performed within 8 weeks prior to enrollment

  • For all patients, an MRI of the brain (with orbital cuts for optic pathway tumors) and/or spine (depending on the site(s) of primary disease) with and without contrast must be performed within 8 weeks prior to enrollment

  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age

  • Patients must have the ability to swallow whole capsules

  • All patients and/or their parents or legal guardians must sign a written informed consent

  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

  • All patients have signed an appropriate consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form (if applicable)

  • All patients have been consented and enrolled on APEC14B1 (NCT02402244) Part A for Pre-Enrollment Eligibility Screening for ACNS1833

Exclusion Criteria:

  • Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant. Prior surgical intervention (with the exclusion of laser interstitial thermal therapy [LITT]) is permitted

  • Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible

  • Patients with diffuse intrinsic pontine tumors as seen on MRI (> 2/3 of pons involvement on imaging) are not eligible even if biopsy reveals grade I/II histology

  • Patients may not be receiving any other investigational agents

  • Patients with any serious medical or psychiatric illness/condition, including substance use disorders or ophthalmological conditions, likely in the judgment of the investigator to interfere or limit compliance with study requirements/treatment

  • Patients who, in the opinion of the investigator, are not able to comply with the study procedures are not eligible

  • Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential

  • Lactating females who plan to breastfeed their infants are not eligible

  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 1 week after stopping study therapy are not eligible.

    • Note: Women study participants of child-bearing potential must use acceptable contraception during the study and for 1 week (7 days) after the last dose of selumetinib. Men study participants with sexual partners who are pregnant or who are of child-bearing potential must use acceptable contraception during the study and for 1 week (7 days) after the last dose of study agent. Acceptable contraception includes implants, injectables, or oral contraceptives (all combined with barrier methods), some intrauterine devices (IUDs), vasectomy or abstinence

  • Known genetic disorder that increases risk for coronary artery disease. Note: The presence of dyslipidemia in a family with a history of myocardial infarction is not in itself an exclusion unless there is a known genetic disorder documented

  • Symptomatic heart failure

  • New York Health Association (NYHA) class II-IV prior or current cardiomyopathy

  • Severe valvular heart disease

  • History of atrial fibrillation

  • Current or past history of central serous retinopathy

  • Current or past history of retinal vein occlusion or retinal detachment

  • Patients with uncontrolled glaucoma

    • If checking pressure is clinically indicated, patients with intraocular pressure (IOP) > 22 mmHg or ULN adjusted by age are not eligible

  • Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E

  • Surgery within 2 weeks prior to enrollment, with the exception of surgical biopsy, placement of a vascular access device or cerebral spinal fluid (CSF) diverting procedure such as endoscopic third ventriculostomy (ETV) and ventriculoperitoneal (VP) shunt.

    • Note: Patients must have healed from any prior surgery

  • Patients who have an uncontrolled infection are not eligible

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Arm I (vincristine sulfate, carboplatin)

INDUCTION: Patients receive vincristine sulfate IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and MRI throughout the trial.

MAINTENANCE: Patients receive vincristine sulfate IV on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and MRI throughout the trial.
의약품: Carboplatin

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8
절차: Biospecimen Collection

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집
의약품: Vincristine Sulfate

Given IV

다른 이름들:
  • 온코빈
  • 교크리스틴
  • 류로크리스틴 황산염
  • 류로크리스틴, 설페이트
  • 빈카사르
  • 빈코시드
  • 빈크렉스
  • 빈크리스틴, 설페이트
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies
실험적: Arm II (selumetinib sulfate)

Patients receive selumetinib sulfate PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at baseline and undergo collection of blood and MRI throughout the trial.
절차: Biospecimen Collection

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

절차: Echocardiography Test

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC
의약품: Selumetinib Sulfate

Given PO

다른 이름들:
  • AZD-6244 황산수소
  • AZD6244 황산수소
  • AZD6244 황산수소염
  • 코셀루고
  • 셀루메티닙 황산염

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Event-free survival (EFS)
기간: Up to 10 years from date of randomization

The Kaplan-Meier method will be used to estimate EFS which is defined as the interval from randomization to first occurrence of clinical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause, or to the date of last follow-up. Estimates with 95% confidence intervals will be reported by treatment arm. The hazard ratio with a confidence interval will also be reported to compare treatment arms based on a Cox proportional hazards model stratified by BRAF status, tumor location and size of residual tumor. Will also provide outcome estimates and their associated confidence intervals by sex, race and ethnicity, as descriptive summaries of outcome.
Up to 10 years from date of randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Radiographic tumor response rate
기간: Up to 10 years

Percentages of patients with responses (complete or partial response) will be reported by treatment arm with 95% confidence intervals. The result of an exact binomial test to test for the difference in response rates between treatment arm will also be reported. Will also provide outcome estimates and their associated confidence intervals by sex, race and ethnicity, as descriptive summaries of outcome.
Up to 10 years
Overall survival (OS)
기간: Up to 10 years from date of randomization

The Kaplan-Meier method will be used to estimate OS by treatment arm, defined as the interval from randomization to death from any cause, or to the date of last follow-up. Estimates with confidence intervals will be reported by treatment arm. Will also provide outcome estimates and their associated confidence intervals by sex, race and ethnicity, as descriptive summaries of outcome.
Up to 10 years from date of randomization
Number of patients who experience an improvement in visual acuity (VA)
기간: After the first 12 months of treatment

Numbers of patients that show improvement in VA after 12 months of treatment will be reported by treatment arm. Patients with at least 1 impaired eye are evaluable. In a patient with a unilateral optic nerve glioma, only the affected eye is considered. In patients with bilateral visual impairment, if VA improves in 1 eye but worsens in the other, the patient will be coded as a treatment failure, whereas if 1 eye improves and the other is at least stable, the patient will be coded as a success.
After the first 12 months of treatment
Change in motor function
기간: After 48 weeks of therapy

Motor function is measured using the Vineland-3 Motor Scale. Only patients with motor function deficits at baseline are included. Magnitudes of change from baseline between the 2 treatment arms and provide a 90% 2-sided confidence interval for this difference.
After 48 weeks of therapy
Change in quality of life (QOL)
기간: Baseline and 9 months after treatment initiation

QOL will be measured using the PedsQL Total Scale Score as measured from the validated PedsQL Generic Module (for children 2-21 years old). Mean differences in the total scale score between 9 months and baseline will be reported by treatment arm. The results of 2-sample t-test comparing differences in the QOL scores between the 2 arms will also be reported. If change scores do not follow normal distributions, non-parametric alternatives may be employed for analysis.
Baseline and 9 months after treatment initiation
Processing speed function
기간: Up to 9 months post-treatment initiation

Measured by Wechsler Processing Speed Index (standard score). Scores at 9 months will be summarized by treatment arm and reported as means (with standard deviations) or medians (with ranges) depending on the data distribution.
Up to 9 months post-treatment initiation
Change in executive function
기간: Baseline and 9-months

Executive function will be measured by the Behavior Rating Inventory of Executive Function, Second Edition BRIEF Cognitive Regulation Index (CRI). Summary statistics for the differences in scores from baseline to 9 months will be reported by treatment arm.
Baseline and 9-months

기타 결과 측정

결과 측정
측정값 설명
기간
Change in QOL scores over time
기간: At baseline, 9 months, 30 months, and 60 months after treatment initiation

QOL scores for each domain of the PedsQL Generic module will be summarized by timepoint (4 timepoints) and treatment arm. Mean QOL scores will be reported with standard deviations. If scores do not follow normal distributions, medians and ranges will be reported instead.
At baseline, 9 months, 30 months, and 60 months after treatment initiation
Change in neurocognitive functioning scores over time
기간: At baseline, 9 months, 30 months, and 60 months after treatment initiation

Neurocognitive functioning scores for each index/scale of the Behavior Rating Inventory of Executive Function, Second Edition/Preschool Version/Adult will be summarized by timepoint (4 timepoints) and treatment arm. Mean scores will be reported with standard deviations. If scores do not follow normal distributions, medians and ranges will be reported instead.
At baseline, 9 months, 30 months, and 60 months after treatment initiation
EFS by sex
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by sex.
Up to 10 years from date of randomization
EFS by race
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by race.
Up to 10 years from date of randomization
EFS by ethnicity
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by ethnicity.
Up to 10 years from date of randomization
OS by sex
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by sex.
Up to 10 years from date of randomization
OS by race
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by race.
Up to 10 years from date of randomization
OS by ethnicity
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by ethnicity.
Up to 10 years from date of randomization
Neurocognitive outcomes by sex
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by sex.
Up to 10 years from date of randomization
Neurocognitive outcomes by race
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by race.
Up to 10 years from date of randomization
Neurocognitive outcomes by ethnicity
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by ethnicity.
Up to 10 years from date of randomization
QOL by sex
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by sex.
Up to 10 years from date of randomization
QOL by race
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by race.
Up to 10 years from date of randomization
QOL by ethnicity
기간: Up to 10 years from date of randomization

Estimates of treatment effect and the corresponding 95% confidence intervals will be provided by ethnicity.
Up to 10 years from date of randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

National Cancer Institute (NCI)

수사관

  • 수석 연구원: Peter M de Blank, Children's Oncology Group

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 1월 31일

기본 완료 (추정된)

2030년 12월 31일

연구 완료 (추정된)

2030년 12월 31일

연구 등록 날짜

최초 제출

2019년 11월 15일

QC 기준을 충족하는 최초 제출

2019년 11월 15일

처음 게시됨 (실제)

2019년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NCI-2019-07600
  • U10CA180886 (미국 NIH 보조금/계약)
  • NCI-2019-07600 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • ACNS1833 (기타 식별자: CTEP)
  • ACNS1833 (기타 식별자: Children's Oncology Group)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다